“Dabigatran etexilate is an oral direct thrombin inhibitor that has recently been approved for anticoagulation of nonvalvular atrial fibrillation (AF). While this medication possesses a number of characteristics that make it an attractive alternative to warfarin, its use for other indications currently remains untested. ... Off-label use of novel drugs can jeopardize potential future applications in new disease contexts and should be avoided until data from well-designed clinical studies is available”.
Price J., Hynes M., Labinaz M., Ruel M., Boodhwani M.
Тромбоз механического клапана на дабигатране.
Mechanical Valve Thrombosis With Dabigatran.
J Am Coll Cardiol. 2012;(online September 26):. doi:10.1016/j.jacc.2012.06.039
Цитата с сайта http://www.athero.ru/